EP0190296A1 - Opiate antagonists - Google Patents

Opiate antagonists

Info

Publication number
EP0190296A1
EP0190296A1 EP19850904076 EP85904076A EP0190296A1 EP 0190296 A1 EP0190296 A1 EP 0190296A1 EP 19850904076 EP19850904076 EP 19850904076 EP 85904076 A EP85904076 A EP 85904076A EP 0190296 A1 EP0190296 A1 EP 0190296A1
Authority
EP
European Patent Office
Prior art keywords
formula
general formula
compound
group
opiate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19850904076
Other languages
German (de)
French (fr)
Inventor
Kenneth Neville Wynne
Jaroslav Haman Boublik
Olaf Heino Drummer
Ian David Rae
John Watson Funder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth of Australia
Original Assignee
Commonwealth of Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commonwealth of Australia filed Critical Commonwealth of Australia
Publication of EP0190296A1 publication Critical patent/EP0190296A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom

Definitions

  • This invention relates to the identification and isolation of compounds having opiate receptor binding activity, to the synthesis thereof, and to the use of such compounds as opiate narcotic antagonists.
  • R, , R 2 and R_ groups represents a feruloyl or isoferuloyl group of the formula II or III, respectively:
  • R.. , R_ and R-. are as defined above.
  • Feruloylquinic acids of the general formula IV are known to occur in green coffee beans (Clifford, M.N. , Food Chem. 4, 146-149 (1961) ) .
  • Compounds of the general formula I may also be isolated directly from coffee beans which have been roasted, ground and extracted with water and from instant coffee. This process, which includes thes teps of adsorption on an ion exchange resin followed by chromatography to isolate fractions having the desired activity, is described in greater detail below.
  • the present invention also provides a process for the preparation of the compounds of the general formula I, above, which process comprises the reaction of quinic- 1,3-lactone (or quinide) of the formula V:
  • each R separately represents H or a removable hydroxy protecting group, with a ferulic or isoferulic acid of the formula VI or VII, respectively:
  • R. is an acetyl or other hydroxy protecting group, or a reactive derivative thereof, followed by removal of the group R. and, if necessary any hydroxy
  • the lactone of the formula V may be prepared from quinic acid by reaction with a condensing agent, for example dicyclohexylcarbodiimide (DCC) , or by other known methods, such as by reaction with gaseous HCl in acetone.
  • a condensing agent for example dicyclohexylcarbodiimide (DCC)
  • DCC dicyclohexylcarbodiimide
  • Removable hydroxy protective groups R may be added by methods known per se in the art.
  • acetylferuloylquinides or acetylisoferuloylquinides the acetyl group is removed by brief exposure to methanolic K 2 C0 3-
  • the process of the invention involves the reaction of quinic-1,3-lactone of the formula
  • R. is an acetyl or other hydroxy protecting group, followed by removal of the group R.. Similarly, the protecting isopropylidene or trichloroethoxy carbonyl groups are removed to give in the cases of VA, VB, and VC, the 1,5, and 4-substituted esters of quinic-l,3-lactone respectively.
  • Compounds of the general formula I exhibit significant opiate receptor binding activity, and thus have potential for use as opiate antagonists in reversing the toxic effects of opiate narcotic analgesics such as morphine, for example in the treatment of opiate narcotic overdosage and in the reversal of respiratory depression following the use of narcotics during surgery.
  • opiate narcotic analgesics such as morphine
  • the present invention therefore also extends to pharmaceutical compositions comprising a compound of the general formula I, together with one or more pharmaceutically acceptable carrier or diluent; as well as to methods of treatment of the conditions outlined above, which comprise administration to a patient of a compound of the general formula I, or a pharmaceutical composition containing a compound of the general formula I.
  • GC-MS gas chromatogram-mass spectra
  • Principal total ion peaks of the gas chromatogram contained M/Z 249 (derivatized feruloyl ions) and five of these also exhibit the same molecular ion M/Z 566.
  • the five, with similar mass spectra, are from the possible feruloylquinides of general formula I. Some may be cis-isomers produced as artifacts by the conditions during gas chromatography.
  • Another five hidden peaks of derivatized caffeoyl ions M/Z 307, totalling 10% of the feruloyl ions were also observed and were assumed to represent demethylation that occurred during isolation.
  • Conversion of the roasted bean to instant coffee is estimated to double the concentration of active quinides - possibly to 2% of instant coffee. If this figure is applied to - the ED 50 for instant coffee set out in Table 1 (1.2 mg/ml) it would indicate that feruloylquinides have an ED 5Q of 0.024 mg/ml. The finding of 0.05 mg/ml for crude feruloylquinides indicates that one or more of the isomeric forms of feruloylquinide produce the predominant opiate receptor binding activity of instant coffee.
  • ED-.'s represent the concentration of material required to displace by 50% the binding of 3 H-naloxone in a crude rat brain membrane preparation as described in detail hereinafter. Samples were dissolved in 0.05 M Tris (HCl buffer at pH 7.4 and assayed in triplicate' at 3 to 5 concentrations. ED-, values are determined graphically on log transformed data.
  • Figure 2 shows mass chromatograms of (A) TMS derivatives of instant coffee extract (Fig.l) showing time profiles of total ion current, ions m/z 249 (feruloyl ion), and m/z 566 and (b) TMS derivatives of 4- and 5-caffeoylquinides showing time profiles of total ion current, ion m/z 307 (caffeoyl ion) , and m/z 624 (M+) .
  • Derivatives were prepared by reaction of sample with 100 ⁇ l trimethylsilylimidazole (Pierce) and
  • the receptor assay system was based on that of Pert and Snyder (Pert, C.B. & Snyder, S.H., Proc. Natu. Acad. Sci. U.S.A. 70, 2243-2247, (1973) ).
  • Male Sprague-Dawley rats were killed by decapitation, and brains minus cerebellum homogenized in 25x vol of 0.05 Tris-HCl, pH 7.4 buffer using a Brinkmarin Polytron on setting 4 for 5 s. The homogenate was centrifuged for 20 min at 18,000 g, and the pellet resuspended in 25x vol buffer.
  • Acetylferulic acid was prepared after the method of L.S.Fosdick & A.C.Starke, J.Am.Chem.Soc. 6J2, 3352-5 (1940).
  • Acetylferuloylquinide from the previous preparation was dissolved in methanol and K ⁇ CO ⁇ dissolved in aq.methanol was added.
  • acetylisoferulic acid prepared previously by J.Pacsu and C.Stieber, Ber. 62B, 2974-9 (1929)
  • acetylisoferuloylquinides may be prepared exactly as described previously • for acetylferuloylquinides.
  • the acetyl group may be removed by the method described previously to yield the 1-feruloyl ester of quinic-1,3-lactone.
  • the 1-isoferuloyl ester of quinic-l,3-lactone may be prepared.
  • Example 4 The general procedures of Example 4, may be repeated using 2,2,2-trichloroethoxycarboxy esters as protecting groups on the 1-, or 1- and 5-, hydroxy groups of quinic-1,3—lactone, following ' the methods for synthesis and facile hydrolysis described by T.B.Windolz and D.B.R.Johnston, Tetrahedron Lett. 2555 (1967) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés de formule générale (I), où l'un des groupes R1, R2 et R3 représente un groupe féruloyle ou isoféruloyle de formule (II) ou (III), respectivement, et les autres groupes R1, R2 et R3 représentent l'hydrogène. Ces composés présentent une activité de récepteurs d'opiate et peuvent être utilisés dans le traitement des effets toxiques d'analgésiques narcotiques à base d'opiate. Est décrite la préparation de ces composés par extraction du café et par des procédés de synthèse.Compounds of general formula (I), where one of the groups R1, R2 and R3 represents a feruloyl or isoferuloyl group of formula (II) or (III), respectively, and the other groups R1, R2 and R3 represent hydrogen . These compounds exhibit opiate receptor activity and can be used to treat the toxic effects of opiate-based narcotic pain relievers. The preparation of these compounds is described by extraction of coffee and by synthetic methods.

Description

"OPIATE ANTAGONISTS"
This invention relates to the identification and isolation of compounds having opiate receptor binding activity, to the synthesis thereof, and to the use of such compounds as opiate narcotic antagonists.
Previous reports have shown that solutions of instant coffee powders, both normal and decaffeinated, contain ligands for opiate receptors with characteristics similar to those of known opiate antagonists such as naloxone (Boublik, J.H. et al. Nature 301, 246-248 (1983) ). Further work has now enabled the isolation of the principal component of this opiate receptor binding activity and established the identity thereof.
According to the present invention there are provided compounds having opiate receptor binding activity of the general formula I
OR, wherein one of the R, , R2 and R_ groups represents a feruloyl or isoferuloyl group of the formula II or III, respectively:
and
and the other R, , R~ and R., groups represent hydrogen.
Compounds of the general formula' I above may be derived by pyrolysis from the corresponding feruloylquinic acids of the general formula IV
wherein R.. , R_ and R-. are as defined above.
Feruloylquinic acids of the general formula IV are known to occur in green coffee beans (Clifford, M.N. , Food Chem. 4, 146-149 (1961) ) . Compounds of the general formula I may also be isolated directly from coffee beans which have been roasted, ground and extracted with water and from instant coffee. This process, which includes thes teps of adsorption on an ion exchange resin followed by chromatography to isolate fractions having the desired activity, is described in greater detail below.
The present invention also provides a process for the preparation of the compounds of the general formula I, above, which process comprises the reaction of quinic- 1,3-lactone (or quinide) of the formula V:
wherein each R separately represents H or a removable hydroxy protecting group, with a ferulic or isoferulic acid of the formula VI or VII, respectively:
wherein R. is an acetyl or other hydroxy protecting group, or a reactive derivative thereof, followed by removal of the group R. and, if necessary any hydroxy
1 4 protecting groups R .
The lactone of the formula V may be prepared from quinic acid by reaction with a condensing agent, for example dicyclohexylcarbodiimide (DCC) , or by other known methods, such as by reaction with gaseous HCl in acetone. Removable hydroxy protective groups R may be added by methods known per se in the art.
In one embodiment of the process of this invention, quinic acid is converted to quinic-1,3-lactone (V) in the presence of DCC,: and then acetyl ferulic acid or acetyl isoferulic acid (VI, VII, R,= CH^CO-) is added. Following the formation of acetylferuloylquinides or acetylisoferuloylquinides, the acetyl group is removed by brief exposure to methanolic K2C03-
Preferably, the process of the invention involves the reaction of quinic-1,3-lactone of the formula
OH with the hydroxyls on carbons 4 and 5 blocked with an isopropylidene group (formula VA) , or the hydroxyl on carbon 1 protected with a 2,2,2-trichloroethoxy carboxy ester (formula VB) or both hydroxyls 1 and 5 similarly esterified. (formula VC) :
with a feruloyl or isoferuloyl chloride of formula VIII or IX respectively.
wherein R. is an acetyl or other hydroxy protecting group, followed by removal of the group R.. Similarly, the protecting isopropylidene or trichloroethoxy carbonyl groups are removed to give in the cases of VA, VB, and VC, the 1,5, and 4-substituted esters of quinic-l,3-lactone respectively.
Compounds of the general formula I exhibit significant opiate receptor binding activity, and thus have potential for use as opiate antagonists in reversing the toxic effects of opiate narcotic analgesics such as morphine, for example in the treatment of opiate narcotic overdosage and in the reversal of respiratory depression following the use of narcotics during surgery.
The present invention therefore also extends to pharmaceutical compositions comprising a compound of the general formula I, together with one or more pharmaceutically acceptable carrier or diluent; as well as to methods of treatment of the conditions outlined above, which comprise administration to a patient of a compound of the general formula I, or a pharmaceutical composition containing a compound of the general formula I.
Preliminary attempts to isolate opiate receptor-active material in instant coffee by solvent extraction and chromatography indicated that activity was associated with yellow pigment having an absorption maximum of 325 nm, which is characteristic of the chlorogenic acids. On silica chromatography, the activity was less polar than the most nonpolar of the chlorogenic acids, i.e. the dicaffeoylquinic acids or "isochlorogenic acid" as isolated from green coffee beans (Sondheimer, E. , Szymanski, CD. & Corse, J. . J. Agr. Food Chem. 9, 146-149 (1961) ). Further, it was non-acidic, being not adsorbed by DEAP-LH20 anion exchanger (acetate-form) in 72% aq. ethanol (Setchell, K.D.R. , Alme, B. , Axelson, M. & Sjovall, J. J.steroid Biochem. 7, 615-629 (1976) ). In common with many of the caffeoylquinic acids, it was prone to oxidation, particularly on silica during chromatography. Isolation was monitored by an assessment of EDj.,- values in an opiate receptor assay described hereinafter in detail (see Table 1 below) . Fig.l details the chosen isolation scheme which resulted in a twenty-fold increase in specific activity, i.e. from an ED [-n of 1.2 mg/ l for instant coffee to 0.05 mg/ml for the final extract. The GC-MS (gas chromatogram-mass spectra) findings are presented in Fig.2A. Principal total ion peaks of the gas chromatogram contained M/Z 249 (derivatized feruloyl ions) and five of these also exhibit the same molecular ion M/Z 566. The five, with similar mass spectra, are from the possible feruloylquinides of general formula I. Some may be cis-isomers produced as artifacts by the conditions during gas chromatography. Another five hidden peaks of derivatized caffeoyl ions M/Z 307, totalling 10% of the feruloyl ions were also observed and were assumed to represent demethylation that occurred during isolation.
i has been shown (Reichstein, T. Helv. chim.
Acta 15, 1450-1453 (1932) ) that a compound, subsequently called Hauschild's Substance, isolated from the beverage "mate" (Hauschild, . Mitt. Levensmitt. Hyg. 26, 329 (1935) (Chem. Abs. 30, 3537 (1936) ) was a lactone of neochlorogenic acid (5-caffeoylquinic acid) formed during the preparation of the drink from Ilex paraguariensis. In view of the fact that green coffee beans may contain up to 10%, on a dry weight basis, of chlorogenic acids, of which 75% are caffeoylquinic acids (Clifford, supra) , it is highly probable that
Hauschild's Substance, and other caffeoylquinides, would be present in roasted and instant coffee. To test whether these contribute to opiate receptor activity, pure chlorogenic acid, 3-caffeoylquinic acid, isolated from green coffee beans (Sandheimer et al, supra) was heated to 90°C in saturated NaHC0_ solution for 30 minutes. This is known to produce a mixture of 4- and 5-caffeoylquinic acids (Haslam, E., Makinson, G.K., Naumann, M.O. & Cunningham, J. J.che . Soc. 2137-2146 (1964) ) . The mixed acids were then lactonized by heating to 90°C for 3 hours in glacial acetic acid. Flash chromatography by the same system in Fig.l lead to a product with negligible opiate receptor activity (Table 1). The same product on GC-MS showed two peaks,# presumably 4- and 5-caffeoylquinides (Fig.2B) . Although these probably represent the usually more stable trans isomers and the cis forms still remain to be tested, this is in accordance with the observation (Table 1) that the 3-methyl ether of 3,4-dihydroxystyrene (4-vinylguaiacol) has appreciable opiate receptor binding activity while the unmethylated 'parent compound has none.
It has been noted that opiate receptor activity develops in coffee beans with roasting, and a comparison of the Arabica and Robusta species of coffee shows that the latter can produce a higher level of activity when each is identically roasted, ground, and extracted with hot water (Table 1) . As it is a well documented observation that Robusta green beans contain about twice the level of feruloylquinic acids as Arabica, (Clifford, supra; Rees, D.I. & Theaker, P.D. 8th International Scientific Colloquium on Coffee, Abidjan, 1977, ASIC (Paris) 79-84 (1979) ) , this finding is compatible with the generation of feruloylquinides during roasting and the difference in opiate receptor activity of the two brewed coffees. Robusta green beans can have a content of up to 2% feruloylquinic acids (Rees et al, supra) , so if it is assumed that instant coffee has been manufactured from beans with a 1.5% content, then, in a "medium" roast (Rees et al, supra) , about two-thirds of this could be dehydrated to feruloylquinides. Conversion of the roasted bean to instant coffee is estimated to double the concentration of active quinides - possibly to 2% of instant coffee. If this figure is applied to - the ED50 for instant coffee set out in Table 1 (1.2 mg/ml) it would indicate that feruloylquinides have an ED5Q of 0.024 mg/ml. The finding of 0.05 mg/ml for crude feruloylquinides indicates that one or more of the isomeric forms of feruloylquinide produce the predominant opiate receptor binding activity of instant coffee.
TABLE 1. The half-maximal effective dose (EDo-.u-)* of materials derived from, or known to occur in, roasted coffee.
ED50 (mg/ml)
Brewed Arabica Coffees+ 3.0, 3.9 (14.7 14.6)
Brewed Robusta Coffees+ 2.1, 1.8 (7.6 10.8)'
Instant Coffees (Different
Types) 1.1 ± 0.1 (mean ± s.e'.m. ; n-43)
Product of treatment of instant coffee with Amberlite XAD-2 and C18 silica (Fig.l) 0.45
Flash chromatography fractions
(Fig.l)
No. 7 >10
8 0.35
9 0.25
10 0.1
11 0.05
12,rl3 0.1
14,rl5, .16 0.15
1 , ,18 0.2
19, ,20 0.6
- and 5-caffeoylquinides (see text) >10 3,4-dihydroxystyrene, synthesized (Rahn, . & Konig, .A. J. High Resolution Chromatogr. Commun.l, 69-71 (1978)) >10
4-vinylguaiacol,synthesized
(Reichstein, T. Helv.
Chi . Acta 15, 1450-1453(1932) ) 1.2
TABLE LEGEND
* ED-.'s represent the concentration of material required to displace by 50% the binding of 3 H-naloxone in a crude rat brain membrane preparation as described in detail hereinafter. Samples were dissolved in 0.05 M Tris (HCl buffer at pH 7.4 and assayed in triplicate' at 3 to 5 concentrations. ED-, values are determined graphically on log transformed data.
+ Two varieties each of Arabica and Robusta green beans were roasted to 15% weight loss. Each was ground to a particle size ^0.5 mm and 10 g samples were extracted with 10 ml water at 100°C in a single pass expresso coffee maker. Each brew was lyophilized and dry residues weighed and redissolved for assay. ED^-. values represent the concentrations with respect to the mass of dry residue. Due to different extraction percentages for the four varieties (ranging from 16-27%) , the ED=5f) va ues ln green bean mass equivalents are also presented (in brackets) . Further details of the isolation of opiate receptor-activity material in instant coffee powder, and of the characterisation thereof, and of the synthesis of the compounds of the invention, are set out in the following Examples:
EXAMPLE 1
A. Isolation Scheme (see Figure 1) .
1. An aqueous suspension of instant coffee (2.5 g/100ml) was passed through a column of Amberlite XAD-2 (7 g/g coffee powder) and the column washed with an equal volume of water. Adsorbed material was eluted with 80% aqueous methanol and -the * methanol evaporated _in vacuo. Then residue was adjusted to 20% aqueous methanol.
2. Solution was stirred with reverse phase C18 silica (from Waters SEP-PAK cartridges ) 1 g/10 ml, for at least 10 minutes, filtered, and washed with 20% aqueous methanol until no further colour eluted. Then C18 silica extracted with 60% aqueous methanol (10 ml/g) and filtered solution initially evaporated in vacuo to an aqueous suspension, then, lyophilized to light brown flakes.
3. A column of silica (Merck Kieselgel 60, 230-400 mesh) was prepared for flash chromatography (Still, W.C., ahn, M. & Mitra, A. J. Org. Chem. 43, 2923-2925 (1978) ) with CHC13-CH30H (80:20 v/v) and coffee concentrate applied to the top as a suspension. Volume of developing solvent and size of fractions were as recommended (Still et al, supra) with positive pressure to give a solvent drop of 1 cm/min. After removal of solvent, each fraction was assessed by an ED^- determination in the opiate receptor binding assay as detailed below. The results are shown in Table 1. Fractions with an ED-- of 0.1 mg/ml or less were combined.
4. Preparative gel permeation chromatography using Waters HLPC instrumentation (model 6000A pump, model U 6 injector, model 450 variable wavelength o detector) and a Waters Ultrastyragel 100A column, was carried out with tetrahydrofuran (THF) as solvent at 1 ml/min. Injections of extract in THF (10 mg/ml) was 100 μl and 0.2 ml fractions collected. Analytical assessment of each fraction was made with 3 μl injections and detection at 300 rim. Most of the UV absorbing material had a retention volume of 6.93 ml and those preparative fractions with a single peak at 6.93 ml, were combined and again reprocessed by preparative GPC as above. After the second purification, the combined fractions were evaporated with N- and dried prior to GC-MS.
Figure 2 shows mass chromatograms of (A) TMS derivatives of instant coffee extract (Fig.l) showing time profiles of total ion current, ions m/z 249 (feruloyl ion), and m/z 566 and (b) TMS derivatives of 4- and 5-caffeoylquinides showing time profiles of total ion current, ion m/z 307 (caffeoyl ion) , and m/z 624 (M+) . Derivatives were prepared by reaction of sample with 100 μl trimethylsilylimidazole (Pierce) and
100 μl dry acetonitrile for 30 min at 60°C in sealed vials. One icrolitre was injected into gas chromatograph with temperature program 200°C to 300°C at 10°C/min with final hold time of 10 in at 300°C. Carrier gas was helium at 30 ml/min and injection and detector zones were 300°C. The column (2 m x 2 mm ID) was packed with 3% SP2100 on chro osorb W. Detection of the effluent was by mass spectrometry (Finnigan Model 4021) using electron impact ionization at 70 eV and a source temperature of 250°C.
B. Opiate Receptor Binding Assay
The receptor assay system was based on that of Pert and Snyder (Pert, C.B. & Snyder, S.H., Proc. Natu. Acad. Sci. U.S.A. 70, 2243-2247, (1973) ). Male Sprague-Dawley rats were killed by decapitation, and brains minus cerebellum homogenized in 25x vol of 0.05 Tris-HCl, pH 7.4 buffer using a Brinkmarin Polytron on setting 4 for 5 s. The homogenate was centrifuged for 20 min at 18,000 g, and the pellet resuspended in 25x vol buffer. Aliquots (0.5 ml) of this preparation were incubated with 1 nM 3H-naloxone (40 Ci mmol -1; NEN) alone or with various test preparations. Incubations were done in 0.5% BSA and 10% Trasylol for 30 min at
25°C, and terminated by rapid vacuum filtration through Whatman GF/B glass fibre filters pre-wetted with buffer containing 0.5% BSA. Filters were washed with 5 ml buffer, air-dried and added to 10 ml non-aqueous scintillant.
EXAMPLE 2 a. Preparation of quinic-1,3-lactone
Quinic acid in anhydrous DMF (dimethylformamide) was added to DCC (dicyclohexylcarbodiimide) in DMF magnetically stirred at room temperature. Pyridine was added and after stirring for 30 minutes, the solution went turbid. Stirring was continued for a further two and a half hours.
b. Preparation of acetylferulic acid
Acetylferulic acid was prepared after the method of L.S.Fosdick & A.C.Starke, J.Am.Chem.Soc. 6J2, 3352-5 (1940).
c. Preparation of acetylferuloylquinides
Quinic-1,3-lactone and acetylferulic acid prepared as described above were reacted to form the desired esters.
d. Preparation of Feruloylquinides
Acetylferuloylquinide from the previous preparation was dissolved in methanol and K^CO^ dissolved in aq.methanol was added.
EXAMPLE 3
Using acetylisoferulic acid (prepared previously by J.Pacsu and C.Stieber, Ber. 62B, 2974-9 (1929)), acetylisoferuloylquinides may be prepared exactly as described previouslyfor acetylferuloylquinides.
Removal of the acetyl group as described above yields the desired isoferuloylquinides.
EXAMPLE 4 Reaction of 4,5-O-isopropylidenequinide (prepared as described by H.O.L.Fischer, Chem.Ber. 5_4, 775-83 (1921) ) with acetyl feruloyl chloride (prepared as described by L.S.Fosdick and A.C.Starke, supra) , yields l-O-acetylferuloyl-4,5-O-isopropylidenequinide. The hydrolytic removal of the 4,5-O-isopropylidene group from the 1-O-substituted quinide may be performed by known methods (for example, as described by J.D.Elliott, M. Hetmanski, R.D.Stoodley, M.N. Palfreyman, J.C.S.Perkin I, 1782-88 (1981)). The acetyl group may be removed by the method described previously to yield the 1-feruloyl ester of quinic-1,3-lactone.
By analogous methods using acetylisoferuloyl chloride instead of acetylferuloyl chloride, the 1-isoferuloyl ester of quinic-l,3-lactone may be prepared.
EXAMPLE 5
The general procedures of Example 4, may be repeated using 2,2,2-trichloroethoxycarboxy esters as protecting groups on the 1-, or 1- and 5-, hydroxy groups of quinic-1,3—lactone, following 'the methods for synthesis and facile hydrolysis described by T.B.Windolz and D.B.R.Johnston, Tetrahedron Lett. 2555 (1967) .
EXAMPLE 6
Hydrolytic removal of 4,5-O-isopropylidene group from 1-O-acetylferuloyl-4,5-0-isopropylidenequinide (described as an intermediate in the synthesis of 1-feruloylquinic acid by A.Zane and S.H.Wender, Chem.S Ind. 1034-5 (1965)) by the method of Elliott et al; supra, followed by removal of the acetyl group by the method described previously yields the 1-feruloyl ester of quinic-l,3-lactone.

Claims

CLAIMS :
1. A compound having opiate receptor binding activity of the general formula I:
wherein one of the R-, R2 and R_ groups represents a feruloyl or isoferuloyl group of the formula II or III, respectively:
and
and the other R, , R2 and R~ represent hydrogen.
2. A compound of the general formula I defined in claim 1, in substantially pure form.
3. A process for the preparation of a compound of the general formula I as defined in claim 1, which comprises extraction from instant coffee or from coffee beans which have been roasted, ground and extracted with water, said extraction including the steps of adsorption on an ion exchange resin, followed by chromatography to isolate fractions having the desired activity.
4. A process for the preparation of a compound of the general formula I as defined in claim 1, which comprises pyrolysis of a corresponding feruloylquinic acid of the general formula IV:
wherein R., R2 and R_ are as defined in claim 1.
5. A process for the preparation of a compound of the general formula I as defined in claim 1, which process comprises the reaction of quinic-l,3-lactone of the formula V:
wherein each R. separately represents H or a removable hydroxy protecting group, with a ferulic or isoferulic acid of the formula VI or VII, respectively:
wherein R. is an acetyl or other hydroxy protecting group, or a reactive derivative thereof, followed by removal of the group R. and, if necessary, any hydroxy
1 4 protecting group R .
6. A process as defined in claim 5, which comprises the reaction of quinic-1,3-lactone of the formula
with the hydroxyls on carbons 4 and 5 blocked with an isopropylidene group (formula VA) , or the hydroxyl on carbon 1 protected with a 2,2,2-trichloroethoxy carboxy ester (formula VB) or both hydroxyls 1 and 5 similarly esterified (formula VC) :
with a feruloyl or isoferuloyl chloride of formula VIII or IX respectively:
wherein R4 is an acetyl or other hydroxy protecting group, followed by removal of the group R. and the protecting isopropylidene or 2,2,2-trichloroethoxy carbody groups.
7. A pharmaceutical composition for the treatment of the toxic effects of opiate narcotic analgesics, comprising a compound of the general formula I as defined in claim 1, together with one or more pharmaceutically acceptable carriers or diluents therefor.
8. A method of treatment of the toxic effects of opiate narcotic analgesics, which method comprises administration of an effective amount of a compound of the general formula I as defined in claim 1, or of a pharmaceutical composition containing a said compound.
9. Use of a compound of the general formula I as defined in claim 1, for the treatment of the toxic effects of opiate narcotic analgesics, or for the manufacture of a pharmaceutical composition for the treatment of the toxic effects of opiate narcotic analgesics.
EP19850904076 1984-08-24 1985-08-23 Opiate antagonists Withdrawn EP0190296A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU6761/84 1984-08-24
AU676184 1984-08-24

Publications (1)

Publication Number Publication Date
EP0190296A1 true EP0190296A1 (en) 1986-08-13

Family

ID=3697344

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19850904076 Withdrawn EP0190296A1 (en) 1984-08-24 1985-08-23 Opiate antagonists

Country Status (2)

Country Link
EP (1) EP0190296A1 (en)
WO (1) WO1986001508A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0581980T3 (en) * 1992-08-03 1999-09-27 Nestle Sa 3- and / or 4-substituted quinic acid derivatives and methods for preparing 3- and / or 4-substituted quinic acid
DE69228541T2 (en) * 1992-08-03 1999-08-12 Societe Des Produits Nestle S.A., Vevey Quinic acid derivatives and process for the production of quinic acid derivatives
BR0100444C1 (en) * 2001-01-30 2003-12-02 Laboratorios Biosintetica Ltda Method of obtaining an extract with antidepressant and opioid antagonist properties and of pharmaceutical products obtained from it
CA2347879A1 (en) 2001-05-11 2002-11-11 Vanderbilt University Substituted dicinnamoylquinides and their use in augmentation of adenosine function
US20060286238A1 (en) * 2005-06-20 2006-12-21 The Procter & Gamble Company Processes for isolating bitter quinides for use in food and beverage products
CN108003027B (en) * 2017-12-25 2021-07-06 北京微医智慧信息技术有限责任公司 1-O-caffeoylquinic acid, its derivative, preparation method and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8601508A1 *

Also Published As

Publication number Publication date
WO1986001508A1 (en) 1986-03-13

Similar Documents

Publication Publication Date Title
King et al. Chemistry of phytotoxins associated with Streptomyces scabies the causal organism of potato common scab
US4313946A (en) Chemotherapeutically active maytansinoids from Trewia nudiflora
Iwu et al. Dioscoretine: the hypoglycemic principle of Dioscorea dumetorum
Powell et al. Novel maytansinoid tumor inhibitors from Trewia nudiflora: trewiasine, dehydrotrewiasine, and demethyltrewiasine
Ghedira et al. Four cyclopeptide alkaloids from Zizyphus lotus
Hahn et al. Hydroxycinnamic acid derivatives, caffeoylmalic and new caffeoylaldonic acid esters, from chelidonium majus*, 1
King et al. Isolation and characterization of thaxtomin-type phytotoxins associated with Streptomyces ipomoeae
EP0190296A1 (en) Opiate antagonists
Lindsay The alkaloids of Margaritaria indica. Part 2. The structures of 4-epiphyllanthine, margaritarine and the structural revision of securinol A
US4298525A (en) Bis-indole-alkaloid
TAKEDA et al. Studies on the bacterial gall of Myrica rubra: isolation of a new [7, 0]-metacyclophan from the gall and DL-β-phenyllactic acid from the culture of gall-forming bacteria
Gu et al. Minor withanolides from Physalis philadelphica: structures, quinone reductase induction activities, and liquid chromatography (LC)-MS-MS investigation as artifacts
Rasheed et al. Hirsutine: A new alkaloid from Cocculus hirsutus
Chatterjie et al. Isolation and stereochemical identification of a metabolite of naltrexone from human urine
Pelletier et al. Alkaloids of Delphinium barbeyi
Hirai et al. Isolation and structure elucidation of fecapentaenes-12, potent mutagens from human feces
Ferris et al. Lythraceae alkaloids. VIII. Structure and stereochemistry of the biphenyl ether alkaloids from Decodon verticillatus
Thomas et al. 15-(14'-eburnamyl) pleiocarpinine (pleiomutine). A new dimeric indole alkaloid from Pleiocarpa mutica Benth
Chimichi et al. Complete assignment of the 1H and 13C NMR spectra of secoisolariciresinol diglucoside, a mammalian lignan precursor isolated from Linum usitatissimum
de Araújo-Júnior et al. Alkaloids and diterpenes from Croton moritibensis
Lavie et al. Trechonolide A, a new withanolide type from Trechonaetes laciniata
Costa et al. Indole alkaloids from the roots of an African plant Securidaca longipedunculata. I. Isolation by column chromatography and preliminary structural characterization by mass spectrometry
Vecchietti et al. Alkaloids of Ocotea acutangula
EP3255031B1 (en) Compound, and separation method, synthesis method and use thereof
Speranza et al. Isolation and chemical characterization of a new constituent of Cape Aloe having the 1, 1-diphenylethane skeleton

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB IT LI NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19860729

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RAE, IAN, DAVID

Inventor name: WYNNE, KENNETH, NEVILLE

Inventor name: FUNDER, JOHN, WATSON

Inventor name: BOUBLIK, JAROSLAV, HAMAN

Inventor name: DRUMMER, OLAF, HEINO